Company Profile

Aucta Pharma (AKA: Aucta Pharmaceuticals LLC~Aucta )
Profile last edited on: 12/31/20      CAGE: 6SUP2      UEI:

Business Identifier: Improved drug delivery
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

675 US Highway One
North Brunswick, NJ 08902
   (732) 640-0030
Location: Multiple
Congr. District: 12
County: Middlesx

Public Profile

Aucta Pharmaceuticals, Inc. (AUCTA, Latin-improved, enhanced) is a technology based product company focusing on creating better products of anch ored in a proven molecule. Using 505(b)(2) regulatory pathway, through innovation, Aucta is creating new therapeutics, including new dosage form, new dosing regimen and new indications. With operations in New Jersey, U.S. and Shanghai, China. the firm has a therapeutic focus in CNS , Dermatology and Pediatric is patient centric by continuously bringing improved form of proven molecule into the market place.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2013 1 NIH $224,284
Project Title: Multiparticulate Dispersive Tablet for Pediatric Anti-TB
2013 1 NIH $224,284
Project Title: Improved Formulations for Anti-Tuberculosis Drugs

Key People / Management

  Shoufeng Li -- CEO

  Fredrick Liquori

  Soby Fennell -- Vice President, Regulatory Affair

  Lixin Gong -- Senior Director, Analytical Development

  Enxian Lu -- General Manager

  Hongyan Ma -- Vice President

  Qiaolin Ren -- Senior Director, Product Development

  Richard Yuan -- Director, Quality Management

  Brian Zorn -- Pharm D, Consultant, Commercial Development

Company News

There are no news available.